Health Affairs, 24, no. 3 (2005): 694-696 doi: 10.1377/hlthaff.24.3.694 © 2005 by Project HOPE	New Online   New Issue: China & India   Obesity In China   Pay Cuts For Medicare Docs   Access To Care Woes

This Article Full Text (HTML) Reprint (PDF) Submit a response to this article Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services E-mail this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to My Personal Archive Download to Citation Manager Reprints & Permissions Citing Articles Citing Articles via ISI Web of Science (3) Citing Articles via Google Scholar Google Scholar Articles by Danzon, P. Articles by Pereira, N. S. Search for Related Content PubMed PubMed Citation Articles by Danzon, P. Articles by Pereira, N. S. Related Collections Consumer Issues Health Promotion/Disease Prevention International Issues Vaccines Public Health Research And Technology

Financing

PERSPECTIVE

Why Sole-Supplier Vaccine Markets May Be Here To Stay

Given the structure of costs, demand, and competition, vaccine markets reach long-run equilibrium with one or very few suppliers at any point in time. Sole suppliers are less likely to exit and may have lower total social costs. Vaccine markets are dynamically competitive, with new, superior products displacing older, inferior products. Measures to address short-run supply disruptions include inventories, foreign sourcing, and improved technologies. Increasing the relative prices paid for new vaccines to levels that more closely reflect their social value compared to other new drugs and biologics is essential to achieving appropriate incentives for allocation of pharmaceutical R&D.

                      What's this?